PFE - What Are Pfizer's Prospects In Obesity Pill Market? Analysts Say Optimism Cautiousness Surround With Data Awaited Next Year | Benzinga
Pfizer Inc (NYSE: PFE) is turning its focus to the weight loss drug market, aiming to capture a $10 billion segment with its experimental obesity pill, danuglipron.
In June, Pfizer discontinued the clinical development of another GLP-1-RA candidate, lotiglipron (PF-07081532), due to pharmacokinetic data from Phase 1 studies and laboratory measurements of elevated transaminases (liver enzymes).
Eli Lilly And Co's (NYSE: LLY) Mounjaro and Novo Nordisk A/S's (NYSE: NVO) Wegovy ...